Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.
ADX-2191-RP-002 (Retinitis Pigmentosa) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called ADX-2191 (the study drug) is a safe and effective option for people with retinitis pigmentosa (RP) due to confirmed rhodopsin mutations.
What is the Condition Being Studied?
Retinitis Pigmentosa (RP)
Who Can Participate in the Study?
Adults ages 21+ who:
- Are diagnosed with RP
- Have rhodopsin mutations
For more information, contact the study team at DEC-RA@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to receive either a high or low dose of the study drug. You will get the study drug as an intravitreal (into the eye) injection once a month for 12 months.
Participation in the study lasts about 13 months and involves 15 visits to our clinic.
Study Details
Full Title
A Randomized, Double-Masked, Controlled, Parallel-Group, Multicenter, Phase?2/3 Clinical Trial Investigating the Efficacy and Safety of ADX-2191 in Adults with Retinitis Pigmentosa - ADX-2191-RP-002
Principal Investigator
Ophthalmologist
Protocol Number
IRB:
PRO00116182
Phase
Phase
II/III
Enrollment Status
Open for Enrollment Soon